When did NOVONESIS (NOVOZYMES) B (NZM2.DE) report earnings last quarter?
NOVONESIS (NOVOZYMES) B (NZM2.DE) last reported earnings on 2/25/2026.

FRA:NZM2 • DK0060336014
Past quarterly earnings results for NOVONESIS (NOVOZYMES) B (NZM2.DE), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in EUR): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 0.45 | 0.54 | -16.62% | 24.45% | 996.6M | 1.029B | -3.15% | -50.21% |
| Q3 2025 | 0.54 | 0.37 | 45.68% | 49.34% | 1.065B | 1.079B | -1.31% | 5.54% |
| Q2 2025 | 0.47 | 0.41 | 14.06% | 45.88% | 1.019B | 1.042B | -2.26% | -44.40% |
| Q1 2025 | 0.42 | 0.39 | 6.35% | 30.36% | 1.078B | 1.074B | 0.34% | 4.62% |
| Q4 2024 | 0.36 | - | 7.40% | 2.002B | 1.002B | 99.78% | 224.28% | |
| Q3 2024 | 0.36 | - | -20.06% | 1.009B | - | 68.85% | ||
| Q2 2024 | 0.32 | - | 10.07% | 1.832B | 980.17M | 86.88% | -56.56% | |
| Q1 2024 | 0.32 | - | -14.99% | 1.03B | - | -77.72% | ||
| Q4 2023 | 0.34 | 0.39 | -14.49% | -21.27% | 617.312M | 625.01M | -1.23% | -86.37% |
| Q3 2023 | 0.45 | 0.38 | 20.08% | -18.75% | 597.574M | 596.24M | 0.22% | -86.32% |
| Q2 2023 | 0.29 | 0.37 | -19.98% | -24.93% | 4.217B | 593.32M | 610.75% | -1.61% |
| Q1 2023 | 0.38 | 0.38 | -1.01% | -5.39% | 4.623B | 614.95M | 651.77% | 5.77% |
| Q4 2022 | 0.43 | 0.37 | 15.90% | 41.96% | 4.529B | 614.49M | 637.03% | 18.13% |
| Q3 2022 | 0.56 | 0.53 | 5.90% | 37.50% | 4.367B | 596.3M | 632.35% | 16.11% |
| Q2 2022 | 0.39 | 0.37 | 4.53% | 2.44% | 4.286B | 549.89M | 679.43% | 19.72% |
| Q1 2022 | 0.40 | 0.40 | -0.77% | -5.45% | 4.371B | 567.95M | 669.61% | 15.76% |
| Q4 2021 | 0.30 | 0.31 | -2.86% | -3.79% | 3.834B | 508.52M | 653.95% | 11.26% |
| Q3 2021 | 0.40 | 0.34 | 19.05% | 19.10% | 3.761B | 499.87M | 652.40% | 9.62% |
| Q2 2021 | 0.38 | 0.34 | 10.88% | 24.49% | 3.58B | 478.37M | 648.37% | 6.90% |
| Q1 2021 | 0.42 | 0.34 | 25.11% | 9.89% | 3.776B | 478.23M | 689.58% | -0.26% |
| Q4 2020 | 0.31 | 0.34 | -7.18% | - | 3.446B | 480.98M | 616.45% | - |
| Q3 2020 | 0.34 | 0.33 | 4.43% | - | 3.431B | 473.42M | 624.73% | - |
| Q2 2020 | 0.31 | 0.31 | -1.75% | - | 3.349B | 453.29M | 638.82% | - |
| Q1 2020 | 0.39 | 0.38 | 0.58% | - | 3.786B | 506.08M | 648.10% | - |
Notes
NOVONESIS (NOVOZYMES) B (NZM2.DE) last reported earnings on 2/25/2026.
NOVONESIS (NOVOZYMES) B (NZM2.DE) missed EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, NOVONESIS (NOVOZYMES) B (NZM2.DE) has beaten EPS estimates in 3 out of 4 releases.